Urgency to treat patients with chronic hepatitis C in Asia

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 5, 2017, Pages 966-974

  Kao, Jia Horng ^a   Ahn, Sang Hoon ^b   Chien, Rong Nan ^c   Cho, Mong ^d   Chuang, Wan Long ^e   Jeong, Sook Hyang ^f   Liu, Chen Hua ^g   Paik, Seung Woon ^h  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Yonsei University College of Medicine   (South Korea)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d Pusan National University Yangsan Hospital   (South Korea)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f Seoul National University Bundang Hospital   (South Korea)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Asia; clinical; HCV clinical trials; HCV treatment; hepatitis C

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ANTIVIRAL THERAPY; ASIA; ASIAN; CHRONIC HEPATITIS C; CLINICAL PRACTICE; EMERGENCY TREATMENT; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ECONOMICS; GENETICS; GENOTYPE; HEALTH CARE COST; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; ASIA; GENOTYPE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; PREVALENCE;

EID: 85018691362     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13709     Document Type: Review

References (75)

1. Messina JP, Humphreys I, Flaxman A et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77–87.
2. World Health Organization. Hepatitis C. World Health Organization. 2015. Available at http://www.who.int/mediacentre/factsheets/fs164/en/
3. Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333–1342.
4. Bennett H, Waser N, Johnston K et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol. Int. 2015; 9: 378–390.
5. Omata M, Kanda T, Yokosuka O et al. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol. Int. 2015; 9: 486–507.
6. Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J. Gastroenterol. 2014; 20: 9270–9280.
7. Smith DB, Bukh J, Kuiken C et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318–327.
8. Yang SS, Kao JH. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2015; 9: 9–20.
9. Bruno S, Crosignani A, Maisonneuve P et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350–1356.
10. Cho EJ, Jeong SH, Han BH et al. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clin Mol Hepatol 2012; 18: 219–224.
11. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 2014; 61: S45–S57.
12. Lee MH, Yang HI, Lu SN et al. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int. J. Cancer 2014; 135: 1119–1126.
13. Seong MH, Kil H, Kim YS et al. Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J. Med. Virol. 2013; 85: 1724–1733.
14. Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med 2015; 30: 423–433.
15. Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: are there still specific problems with genotype 3? World J. Gastroenterol. 2015; 21: 12101–12113.
16. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection, 2014; Geneva: World Health Organization.
17. Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int. J. Nanomedicine 2014; 9: 2051–2067.
18. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment. Pharmacol. Ther. 2013; 37: 921–936.
19. Park SH, Park CK, Lee JW et al. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver 2012; 6: 98–106.
20. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009; 24: 336–345.
21. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865–1876.
22. Zhang L, Jilq N, Shao RX et al. IL28B inhibits hepatitis C virus replication through the JAK–STAT pathway. J. Hepatol. 2011; 55: 289–298.
23. Chen Y, Xu HX, Wang LJ et al. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment. Pharmacol. Ther. 2012; 36: 91–103.
24. Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment. Pharmacol. Ther. 2012; 36: 104–114.
25. Schreiber J, Moreno C, Garcia BG et al. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment. Pharmacol. Ther. 2012; 36: 353–362.
26. Huang CF, Yang JF, Dai CY et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751–759.
27. Hung CH, Lee CM, Lu SN et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int. 2006; 26: 1079–1086.
28. Foster GR, Pianko S, Brown A et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015; 149: 1462–1470.
29. Izumi N, Yokosuka O, Kawada N et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir. Ther. 2014; 19: 501–510.
30. Kao JH, Tung SY, Lee Y et al. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. J. Gastroenterol. Hepatol. 2016; 31:1757–1765.
31. Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect. Dis. 2013; 13: 401–408.
32. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014; 312: 631–640.
33. Zoulim F, Liang TJ, Gerbes AL et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015; 64: 1824–1833.
34. Elbaz T, El-Kassa M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. J Adv Research 2015; 6: 301–310.
35. Kim KH, Jang BK, Chung WJ et al. Peginterferon alpha plus ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis. Korean J Hepatol 2011; 17: 220–225.
36. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370: 1889–1898.
37. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014; 370: 1879–1888.
38. Gane EJ, Hyland RH, An D et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149: 1454–1461.
39. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014; 370: 1594–1603.
40. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014; 370: 1604–1614.
41. Leroy V, Angus P, Bronowicki JP et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 2016; 63: 1430–1441.
42. Poordad F, Schiff ER, Vierling JM et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63: 1493–1505.
43. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083–2091.
44. Kumada H, Suzuki F, Suzuki Y et al. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. J. Gastroenterol. Hepatol. 2016; 31: 14–22.
45. Kao JH, Lee YJ, Heo J et al. All-oral daclatasvir plus asunaprevir for chronic HCV genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016; 36: 1433–1441.
46. Manns M, Pol S, Jacobson IM et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597–1605.
47. Kao JH, Jensen DM, Manns MP et al. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2015.
48. McPhee F, Suzuki Y, Toyota J et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv. Ther. 2015; 32: 637–649.
49. Akuta N, Sezaki H, Suzuki F et al. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J. Med. Virol. 2016.
50. Omata M, Kanda T, Wei L et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol. Int. 2016; 10: 702–726.
51. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology 2016.
52. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370: 1483–1493.
53. Chuang WL, Chien RN, Peng CY et al. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J. Gastroenterol. Hepatol. 2016.
54. Mizokami M, Yokosuka O, Takehara T et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect. Dis. 2015; 15: 645–653.
55. Lawitz E. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 Weeks. J. Hepatol. 2015; 62.
56. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359–365.
57. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 2014; 370: 1983–1992.
58. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 2014; 370: 1973–1982.
59. Kumada H, Chayama K, Rodrigues L Jr et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015; 62: 1037–1046.
60. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013; 368: 1867–1877.
61. Omata M, Nishiguchi S, Ueno Y et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J. Viral Hepat. 2014; 21: 762–768.
62. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 2014; 370: 1993–2001.
63. Kao JH, Chien RN, Chang TT et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int. 2016.
64. ClinicalTrials.gov. Study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese adults with genotype 2 chronic hepatitis C virus (HCV) infection (GIFT-II). 2016. Available at: https://clinicaltrials.gov/ct2/show/results/NCT02023112?term=GIFT-II&rank=1§=X01256 (accessed October 2016).
65. Doss W, Shiha G, Hassany M et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J. Hepatol. 2015; 63: 581–585.
66. Hezode C, Asselah T, Reddy KR et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385: 2502–2509.
67. Kohli A, Kapoor R, Sims Z et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect. Dis. 2015; 15: 1049–1054.
68. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014; 370: 211–221.
69. Wyles DL, Ruane PJ, Sulkowski MS et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N. Engl. J. Med. 2015; 373: 714–725.
70. Nelson DR, Cooper JN, Lalezari JP et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127–1135.
71. Yee BE, Nguyen NH, Jin M et al. Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. BMJ Open Gastroenterol 2016; 3: e000056.
72. Pol S. Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER. J. Hepatol. 2015; 62: S258–S259.
73. Kanda T, Yasui S, Nakamura M et al. Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan. Int J Med Sci 2016; 13: 418–423.
74. Suda G, Kudo M, Nagasaka A et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J. Gastroenterol. 2016; 51:733–740.
75. Honer Zu SC, Maasoumy B, Marra F et al. Drug–drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin. Infect. Dis. 2016; 62: 561–567.